Partners Viatris and Biocon Biologics have announced winning the right to continue providing patients with access to interchangeable biosimilar Semglee (insulin glargine-yfgn) after the US Court of Appeals for the Federal Circuit upheld the US Patent and Trademark Appeal Board’s decisions for unpatentability of five device patents for Sanofi’s Lantus SoloSTAR brand, as well as a district court decision on one of these patents.
US Court Rules In Favor Of Viatris For Interchangeable Semglee
Partners Biocon and Viatris To Continue To Market Insulin Glargine Biosimilar
Viatris and Biocon continue marketing their recently launched interchangeable biosimilar Semglee (insulin glargine-yfgn) as a US appeals court affirms that the challenged claims of five of Sanofi’s Lantus SoloSTAR device patents are unpatentable.
